Supported by existing shareholders and new investors, including tech entrepreneur Urbain Vandeurzen and life sciences entrepreneur Rudi Pauwels
Technology has potential to deliver rapid test results in multiple settings, including future pandemics
For further information please contact:
Marijke Van der Auwera
Director Strategic Marketing
Consilium Strategic Communications (PR Adviser)
+44 20 3709 5700
miDiagnostics is using silicon chip technology which will bring miniaturized, rapid, easy-to-use, lab-quality tests with built-in connectivity direct to the patient and clinician. Combining a nanofluidic processor on a chip and a compact reader, miDiagnostics can measure virtually any biomarker from an easily accessed sample such as drops of fingerprick blood. The Company is developing an extensive portfolio of tests for screening, diagnosis and monitoring of a wide range of health conditions, including infectious diseases. Spun out of the world-leading R&D and innovation hub in nanoelectronics and digital technologies, imec, and a research collaboration with Johns Hopkins University, the leading US research and medical centre, miDiagnostics’ goal is to enable fast, comprehensive and cost-effective health analysis, regardless of location. Based in Leuven, Belgium, miDiagnostics is a privately held company created in 2015.